Phase 2 N=61 A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients
Kidney Transplantation
Primary: Number of Participants With First Biopsy Proven Acute Rejection (BPAR) at Month 6 — 1; 4; 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=74 Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer
Head and Neck Cancer
Primary: Event-free Survival Rate at 1 Year — 0.79 proportion of patients
Phase 2 N=112 Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia
Chronic Primary Insomnia
Primary: Mean Wake Time After Sleep Onset (WASO) — 109.1; 98.7; 90.0; 77.7 minutes — p=0.0018
Phase 2 N=289 Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients
Dry Eye Disease
Primary: Mean Change From Baseline (Week 0) in Visual Analog Scale (VAS) Global Ocular Discomfort Score Over 4 Weeks — 78.3; 76.8; -1.1; -1.7 units on a scale
Phase 2 N=55 Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer
Breast Cancer
Primary: Maximum Feasible Dose in Milligrams Per Meter Squared of Body Surface Area (mg/m2) of Cisplatin and Paclitaxel for Women With Metastatic Breast Cancer — 25; 80 mg/m2
Phase 2 N=59 Effectiveness of Mexiletine for Treating People With Non-Dystrophic Myotonia
Myotonia · Non-Dystrophic Myotonia
Primary: Patient-reported Stiffness on the IVR — 2.53; 4.21; 1.60; 5.27 units on a scale — p=<0.001
Phase 2 N=265 Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer
Ovarian Cancer
Primary: Progression Free Survival (PFS) (According to Response Evaluation Criteria in Solid Tumours [RECIST]) — 8.4; 4.8 Months — p=<0.00001
Phase 2 N=154 Dose-Finding Trial of Polyethylene Glycol 3350 Laxative Plus Electrolytes for the Treatment of Constipation (Protocol P07515)
Constipation
Primary: Percentage of Participants With Successful Bowel Movement (BM) Within 24 Hours of PEG + E Administration — 19.2; 31.4; 19.2 percentage of participants — p=0.1790
Phase 2 N=31 Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients
Parkinson's Disease
Primary: Mean Cortical Amyloid Burden — 0.990; 1.051; 1.146 SUVR
Phase 2 N=71 Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With Complete Response (CR) — 3 participants
Phase 2 N=40 Atorvastatin in New Onset Type 1 Diabetes Mellitus (T1DM)
Type 1 Diabetes
Primary: Efficacy of a Daily Dose of Atorvastatin to Maintain Islet Cell Function as Measured by a 4-hour C-peptide Area Under Curve (AUC) in Patients With Newly Diagnosed Type 1…
Phase 2 N=45 Can Oral T3 Normalize Thyroid Hormone Levels Following Cardiopulmonary Bypass in Children?
Low T3 Syndrome
Primary: Free T3 (FT3) Levels — 3.6; 4.5; 3.9; 3.6 pg/ml — p=<0.05
Phase 2 N=54 Biomarker-based Cockroach Sublingual Immunotherapy Study (BioCSI)
Rhinitis, Allergic, Perennial · Asthma
Primary: Difference in German Cockroach-Specific Serum IgE Over Time — 2.16; 1.12 Ratio — p=<0.0001
Phase 2 N=33 A Study to Determine the Antiviral Activity of TMC310911 When Administered With Ritonavir in Treatment-Naive Human Immunodeficiency Virus - Type 1 (HIV-1) Infected Patients
Human Immunodeficiency Virus Type 1
Primary: Mean Changes From Baseline in Plasma log10 Human Immunodeficiency Virus Type 1 Ribonucleic Acid (HIV-1 RNA) — 4.72; 4.36; 4.78; 4.71 log10 copies/mL
Phase 2 N=36 Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer
Colon Cancer
Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 55 percentage of patients